DaVita (DVA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Kevin Fischbeck from Bank of America Securities reiterated a Sell rating on the stock and has a $126.00 price target.
Kevin Fischbeck has assigned a Sell rating to DaVita’s stock based on a combination of factors surrounding the company’s long-term risks. Despite DaVita’s adjusted operating income exceeding consensus and a guidance indicating potential growth, Fischbeck remains cautious. The company’s future success is heavily reliant on consistent volume growth, which is necessary to overcome concerns related to GLP1. While estimates have been raised and the price objective increased to $126 from $115, the Underperform rating is maintained as Fischbeck awaits further evidence of sustained improvement in volume growth.
Moreover, Fischbeck’s analysis considers the detailed aspects of DaVita’s guidance, which suggests a year-over-year growth, helped by volume growth that can aid in offsetting costs. However, there are concerns about the ability to maintain wage growth and manage cost increases effectively. DaVita’s anticipated revenue and patient care cost growth, driven by rate increases and cost-saving measures, must be weighed against potential headwinds such as minimum wage requirements. Despite some positive indicators in quarterly margins and volume trends, the Sell rating reflects a stance of caution toward the company’s ability to navigate through these challenges and achieve long-term profitability.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
DaVita (DVA) Company Description:
DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services; and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.
Read More on DVA:
